Medicus Pharma公布二期Sknjct-003试验积极顶线数据:200微克组第57天实现73%临床清除率与40%组织学清除率

美股速递
Mar 05

Medicus Pharma Ltd.近日披露了其二期临床试验Sknjct-003的顶线研究结果,数据表现亮眼。在200微克剂量组中,第57天的评估显示,患者达到73%的临床清除率,同时组织学清除率也达到40%。这一数据为后续临床开发提供了有力支持。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10